Yinying Lu

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin, Feng Bi, Shanzhi Gu et al. · Journal of Clinical Oncology · 2021 · 383 citations · Full text

Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma

Chunping Wang, Huaming Wang, Wuwei Yang et al. · Hepatology · 2014 · 278 citations

Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes

Ruidong Xue, Lu Chen, Chong Zhang et al. · Cancer Cell · 2019 · 278 citations · Full text

Liver, Hepatology, Transcriptomic Profiling +10

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 243 citations

Hepatology, Medicine, Pathology +6